Helix BioPharma Corp.
TSX:HBP.TO
1.29 (CAD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) CAD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.26 | 4.532 | 4.434 | 3.841 | 3.591 | 3.424 |
| Cost of Revenue
| 0.013 | 0.012 | 0.173 | 0.212 | 0.056 | 0.167 | 0.13 | 0.134 | 0 | 0 | 0 | 1.741 | 1.642 | 1.669 | 1.516 | 1.239 | 1.139 |
| Gross Profit
| -0.013 | -0.012 | -0.173 | -0.212 | -0.056 | -0.167 | -0.13 | -0.134 | 0 | 0 | 0 | 2.519 | 2.89 | 2.765 | 2.325 | 2.352 | 2.285 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.591 | 0.638 | 0.624 | 0.605 | 0.655 | 0.667 |
| Reseach & Development Expenses
| 5.281 | 4.544 | 5.88 | 5.868 | 5.006 | 6.084 | 7.055 | 5.821 | 4.885 | 5.239 | 5.032 | 7.45 | 7.323 | 10.715 | 10.322 | 5.064 | 4.116 |
| General & Administrative Expenses
| 0.299 | 0.595 | 3.248 | 2.719 | 2.469 | 2.436 | 3.207 | 3.836 | 3.892 | 3.496 | 3.196 | 4.58 | 6.516 | 4.451 | 4.94 | 4.801 | 4.465 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.088 | 1.124 | 1.125 | 0.969 | 0 | 0 |
| SG&A
| 0.299 | 0.595 | 3.248 | 2.719 | 2.469 | 2.436 | 3.207 | 3.836 | 3.892 | 3.496 | 3.196 | 5.668 | 7.64 | 5.576 | 5.909 | 4.801 | 4.465 |
| Other Expenses
| 0 | 0.901 | 0.003 | 0.029 | 0.017 | 0.026 | 0 | 0 | 0 | 0 | 0 | 0 | 0.404 | 0.382 | 0.384 | 0.27 | 1.778 |
| Operating Expenses
| 6.326 | 6.04 | 9.131 | 8.616 | 7.492 | 8.546 | 10.262 | 9.657 | 8.777 | 8.735 | 8.228 | 13.118 | 15.367 | 16.673 | 16.615 | 10.135 | 10.359 |
| Operating Income
| -6.279 | -6.537 | -9.611 | -8.591 | -7.489 | -8.537 | -10.246 | -9.631 | -8.721 | -8.692 | -8.178 | -10.599 | -12.477 | -13.344 | -14.059 | -8.11 | -6.751 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.488 | -2.753 | -3.009 | -3.66 | -2.258 | -1.972 |
| Total Other Income Expenses Net
| 0.003 | -0.027 | 0.037 | 0.03 | -0.037 | -0.088 | 0.187 | -0.034 | -0.059 | 0.01 | -0.016 | -6.824 | 1.463 | -1.079 | -0.025 | 1.299 | -0.818 |
| Income Before Tax
| -6.29 | -6.564 | -9.574 | -8.561 | -7.526 | -8.625 | -10.059 | -9.665 | -8.78 | -8.682 | -8.194 | -17.423 | -11.014 | -14.423 | -14.084 | -6.811 | -7.569 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.09 | -2.43 | -3.253 | -3.667 | -1.897 | -2.211 |
| Income Tax Expense
| 0.014 | -0.484 | -1.663 | 0.449 | 0.001 | 0.029 | 0.014 | 0.017 | -0.037 | 0.019 | -6.624 | 0.017 | 0.334 | 0.046 | 0.018 | 0.153 | 0.105 |
| Net Income
| -6.29 | -6.08 | -7.911 | -9.01 | -7.527 | -8.654 | -10.073 | -9.682 | -8.743 | -8.701 | -1.57 | -17.44 | -11.348 | -14.469 | -14.102 | -6.964 | -7.674 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.094 | -2.504 | -3.263 | -3.671 | -1.939 | -2.241 |
| EPS
| -0.033 | -0.041 | -0.057 | -0.071 | -0.071 | -0.087 | -0.11 | -0.11 | -0.11 | -0.12 | -0.023 | -0.26 | -0.17 | -0.24 | -0.27 | -0.16 | -0.22 |
| EPS Diluted
| -0.033 | -0.041 | -0.057 | -0.071 | -0.071 | -0.087 | -0.11 | -0.11 | -0.11 | -0.12 | -0.023 | -0.26 | -0.17 | -0.24 | -0.27 | -0.16 | -0.22 |
| EBITDA
| -6.266 | -6.525 | -9.412 | -8.38 | -7.364 | -8.372 | -10.116 | -9.497 | -8.588 | -8.46 | -7.782 | -9.775 | -13.348 | -12.915 | -13.773 | -7.84 | -6.305 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.295 | -2.945 | -2.913 | -3.586 | -2.183 | -1.841 |